Prelude Capital Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Prelude Capital Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,900	Closed	-$383K	–	1471
2025 Q1	$383K	Buy	+2,900	New	+$361K	0.03%	605
2020 Q4	–	Sell	-100	Closed	-$3K	–	2108
2020 Q3	$3K	Sell	100 -300	-75%	-$6.84K	﹤0.01%	1644
2020 Q2	$10K	Buy	+400	New	+$8.1K	﹤0.01%	1584

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prelude Capital Management's ITCI Position: Q2 2025 in Review

Prelude Capital Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 79,142 shares — an estimated $10.4M sold.

Prelude Capital Management first reported a position in ITCI in Q1 2016 and held it in 25 quarters. The position peaked at $10.4M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Prelude Capital Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 79,142 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $10.4M.
Prelude Capital Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2016 and held it in 25 quarters.
Prelude Capital Management's Intra-Cellular Therapies Inc. position peaked at $10.4M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.